From the monthly archives: July 2011

A major clinical trial will investigate whether stem cells can be safely used to treat multiple sclerosis (MS).

It is hoped eventually to slow, stop or even reverse the damage MS causes to the brain and spinal cord.

The trial, involving up to 150 patients across Europe, is due to start later this year.

Dr Paolo Muraro from Imperial College London said: “There is very strong pre-clinical evidence that stem cells might be an effective treatment.”

Researchers will collect stem cells from the bone marrow of patients, grow them in the laboratory and then re-inject them into their blood.

The stem cells will make their way to the brain where it is hoped that they will repair the damage caused by MS.

The research has been part-funded by the UK’s MS Society, which is concerned about the availability of unproven stem cell treatments.

In recent years many people living with MS have been attracted to overseas stem cell clinics which claim to cure long-term conditions in exchange for large amounts of money.

But there is no proven stem cell therapy available for MS anywhere in the world.

The MS Society hopes these new trials will eventually lead to a proven treatment – and a reduction in the draw of overseas treatments.

Common condition

MS is the most common neurological condition to affect young people in the UK.

Three million people are thought to be affected worldwide and up to 100,000 in the UK.

The condition is caused by the body’s own immune system attacking and damaging a substance called myelin in the brain and nerve cells.

The myelin damage disrupts messages from the brain to the body which leads to a number of symptoms such as sight loss, bladder and bowel problems, muscle stiffness and eventually physical disability.

Drugs are available to alleviate the symptoms – but they do not prevent the progression of the condition.

Experiments in test tubes and laboratory animals suggest stem cells extracted from bone marrow may be able to offer a more effective treatment.

Their role in the bone marrow is to protect the cells that make blood. But they also seem to protect myelin from attack by the immune system.

There is also some evidence that these cells might also be able to repair damaged tissue.

Hold potential

Dr Doug Brown, of the MS Society, said: “These experiments have confirmed that these stem cells hold that potential – but these need to be confirmed in large scale clinical trials.”

There is some way to go, however, before laboratory promise can be translated into a treatment that can be offered to patients.

The international team will begin so-called phase two clinical trials in six months’ time designed to determine whether the treatment is safe and effective.

It will take five years to carry out and assess the results of the trials after which large phase three trials may be required.

But Dr Muraro believes that the stem cell approach has real potential.

He said: “The great hope is the fact that we are exploiting a biological system that has evolved over millions of years and harnessing it for treatment that takes advantage of the stem cells’ flexibility.”

Sir Richard Sykes, chair of the UK Stem Cell Foundation, said Dr Muraro’s research was the first of its kind to take place in the UK.

“Given the high incidence of MS in the UK in comparison to other countries, I am delighted that we have at last progressed stem cell research to this stage, which will bring much-needed hope to so many people affected by this devastating condition.”

The MS Society is also funding two other stem cell studies.

One, based at Queen Mary Hospital, London will examine how stem cells made from the brains of aborted foetuses can be used to repair nerve damage in people with MS.

The other, based at the University of Nottingham, will compare stem cells from people with a progressive form of MS to those without the condition to aid the discovery of effective treatments.

Source: BBC News © British Broadcasting Corporation 2011 (29/07/11

 

Enhanced by Zemanta

The Alberta government has launched an online questionnaire to study the experiences of Albertans with multiple sclerosis, especially those who have undergone controversial out-of-country Zamboni treatments.

Health Minister Gene Zwozdesky said he’s heard of the procedure leading to adverse effects, including death.

But he’s also listened to stories of the vein procedure — also called liberation treatment — giving people with the neurological disease less pain and a much-improved quality of life.

“It’s compelling enough for us to do something,” the minister said at a press conference in Calgary on Wednesday.

Wednesday’s announcement adds meat to the bones of a push outlined by Zwozdesky last December, when he said $1 million would be put toward studying the treatment. The Alberta Multiple Sclerosis Initiative (TAMSI) will gather information from MS sufferers through a series of questions posted on a secure website. The results will be used to design clinical trials, likely to proceed a year or two from now, the minister said.

MS, a chronic disease, causes physical symptoms ranging form numbness, fatigue and pain to difficulty speaking and inability to control bodily functions.

The treatment was developed by Italian Dr. Pablo Zamboni and involves opening blocked veins in the neck with balloon catheters similar to those used in coronary angioplasty. The treatment is not approved in Canada and hasn’t been scientifically proven.

Dr. Luanne Metz, Calgary MS Clinic Director, said officials will ensure that only MS sufferers participate by asking each online visitor for their Alberta health care number, and matching it with medical records. This will help with the legitimacy of the study, and ensure no one person is able to fill out multiple questionnaires.

Metz notes she wants every Albertan with MS and related conditions to participate, whether they have undergone the treatment or not. The province believes there are 11,000-13,000 MS sufferers in the province, with about 700 new cases diagnosed every year.

Officials want to study the impact of MS in a broad sense. Metz said nobody knows for sure how many Albertans have undergone the vein treatment.

On Wednesday, some MS sufferers in Calgary were supportive of both the government’s survey, and its cautious approach.

“There’s so much unknown,” said Kathy Collins, 60.

After hearing of the positive results, she’s considering undergoing the treatment. But her MS symptoms are not debilitating, and Collins said she’s going to wait for “safe, ethical studies” before making a decision about the invasive procedure.

“It does scare me, absolutely.”

However Calgarian Linda Zack, 58, who paid to have the treatment in Poland last year, said she will not participate in the government’s survey. She said it’s a waste of time.

“They have blinders on. They don’t want to hear the good things,” she said.

Zack, who says she’s suffered from MS for 35 years, said there’s no doubt the treatment works. Feeling in her lower body has returned, she said, and muscle spasms that kept her awake all night are gone.

The Alberta government’s study can be found at http://www.tamsi.ca

Source: The Calgary Herald © Copyright (c) The Calgary Herald (28/07/11)

 

Enhanced by Zemanta
Paolo Zamboni University of Ferrara, Italy

Image via Wikipedia

Invasive treatment of CCSVI is unethical, even in clinical trials, because of “egregious” methodological problems with the single study that supports it, experts argue.

Recent independent studies “not only cast doubt on whether CCSVI is the cause of MS, they call into question whether CCSVI exists at all”, according to a critical analysis published in the Archives of Neurology.

The greatest problem with the results of the controversial study by Pablo Zamboni and colleagues was the apparent confounding of CCSVI treatment with the initiation of disease-modifying therapy, the authors said.

Sixty-five patients were reported to have significantly few relapses and decreased rate of lesions on MRI following percutaneous transluminal angioplasty (PTA).

But the critical analysis showed there was very good reason to think most of these patients (67%) began disease modifying treatment at the start of the treatment trial.

In addition, there was no control group and therefore no blinding of the neurologists or accounting for the placebo effect
.
Zamboni’s earlier paper reporting that CCSVI provided negative and positive predictive values for MS of 100% had no description of how the investigators were blinded.

It appeared that the main interpreting physician in the study was Zamboni himself, raising doubts regarding the objectivity of his interpretations.

Three independent studies conducted through 2010 and 2011 were unable to replicate Zamboni’s prevalence findings, the results of which suggested the venous anomalies were “simply anatomical variants and not pathological”, the review authors said.

Finally there was little reason to think CCSVI would cause MS based on the famous Bradford-Hill criteria for determining causality in biology, they said. The theory failed to satisfy the important criteria of biological plausibility, coherence (with other known data) and analogy (with other disease models).

“Invasive research investigations into treatment of CCSVI are inappropriate until the question of whether CCSVI exists in MS is settled,” they concluded.

Dr Bill Carroll, scientific chairman of MS Research Australia would not say whether or not he agreed with the opinion in the critical review.

Michael Slezak

Source: Neurology Update © Reed Business Information 2011 (26/07/11)

 

Enhanced by Zemanta
Mount Everest from Kalapatthar.

Image via Wikipedia

A team of climbers with MS and Parkinson’s Disease set out to climb Kilimanjaro to prove that a diagnosis with a neurodegenerative disease doesn’t have to mean the end of your active life or your dreams.

 

Seven adventurous men and women with Multiple Sclerosis (MS) and four with Parkinson’s disease (PD), along with nine climbing companions, have reached the highest peak in Africa. This is the first time that a group of people with both of these neurodegenerative diseases have united as a committed team to reach a summit this high, all whilst showing solidarity in supporting one another every step of the way. This climb clearly demonstrated that neurodegenerative diseases do not represent the end of ‘normal’ life, but that people living with the diseases can in fact go on to achieve staggering feats. Mount Kilimanjaro in Tanzania stands at 19,340 feet, not only making it the highest peak in Africa, but also the highest free-standing mountain in the world.

“This ‘Kilimanjaro Leap of Faith Adventure’ was meant to challenge the body, expand the mind and foster courage in dealing with the diagnosis of a neurodegenerative disease. There have been some really tough parts of the trek, especially altitude sickness, for which there is nothing you can do. Imagine that on top of our neurodegenerative diseases. But, we’ve made it and that’s a credit to all of us who believe that we can go beyond the limitations of our disease and still achieve incredible results, both physically and mentally. We have remembered all those with neurodegenerative disease who climb personal mountains each day, as we have taken the steps to this summit,” said trip organizer Lori Schneider, founder of Empowerment Through Adventure.

The climbing group comprises a number of wonderful and diverse individuals. There are musicians, teachers, adventurers, philanthropists, sports enthusiasts, psychologists, social workers, artists, program managers, engineers, parents, and many other unique individuals among the brave people with MS, PD and their climbing companions. The medical team includes an MS researcher and biochemist, a neurologist, a physician’s assistant, physical therapists, sports trainers and the medically trained staff from the climbing company, Alpine Ascents International. Most of the group already enjoy outdoor activities and they have all dedicated themselves to training to prepare themselves for this challenge and adventure. A key attribute of the group is their outstandingly positive outlook, regardless of the hurdles they face, and their unwavering commitment to supporting one another throughout the trip.

“What this wonderful group of people with MS and Parkinson’s disease has done is incredible. When I was first diagnosed with MS I ran away from my life in fear. I left a 22 year marriage, a 20 year teaching career, sold my house, left my community, and tried to run from my MS diagnosis. That changed when I reached the top of the world, becoming the first person with MS to reach the summit of Mount Everest. The idea behind the Kilimanjaro Leap of Faith Adventure was for me to share the lessons I have learned about believing in yourself and following your dreams. I think it’s worked!” continued Lori Schneider.

The Kilimanjaro climb has certainly had its challenges. Some have suffered from altitude sickness, occasionally worsened by the symptoms of their neurodegenerative disease. It is for this reason that three people with MS and five of the climbing companions did not reach the summit. However, everyone has assisted and supported each other every step of the way. All have gone beyond their limitations to redefine who they are and what they are capable of achieving.

Communication activities for the Kilimanjaro Leap of Faith Adventure 2011 are kindly supported by Sanofi.

For team member profiles, press materials, backgrounder, daily updates, visuals and podcasts from the MS / PD climbers and their companions, please visit:http://www.EmpowermentThroughAdventure.com/Kilimicrositehome.htm orhttp://www.EmpowermentThroughAdventure.com

About Empowerment Through Adventure
Lori Schneider started Empowerment Through Adventure to organize adventure activities for others who would like to challenge themselves, step outside of their comfort zone and feel empowered in their own lives. The Kilimanjaro Leap of Faith Adventure is meant to challenge the body, expand the mind and foster courage in dealing with the diagnosis of a neurological disease. As a speaker, Lori Schneider inspires audiences of all kinds with her message about climbing, MS, personal challenges, and believing in yourself.

 

Enhanced by Zemanta
Complete neuron cell diagram. Neurons (also kn...

Image via Wikipedia

The development of a new cell-culture system that mimics how specific nerve cell fibers in the brain become coated with protective myelin opens up new avenues of research about multiple sclerosis. Initial findings suggest that myelin regulates a key protein involved in sending long-distance signals.

Multiple sclerosis (MS) is an autoimmune disease characterized by damage to the myelin sheath surrounding nerve fibers. The cause remains unknown, and it is a chronic illness affecting the central nervous system that has no cure.

MS has long been considered a disease of white matter, a reference to the white-colored bundles of myelin-coated axons that project from the main body of a brain cell. But researchers have discovered that the condition also affects myelinated axons scattered in gray matter that contains main bodies of brain cells, and specifically the hippocampus region, which is important for learning and memory.

Up to half of MS patients suffer cognitive deficits in addition to physical symptoms. Researchers suspect that cognitive problems are caused by abnormal electrical activities of the demyelinated axons extending from hippocampal cells, but until now have not been able to test myelin’s role in this part of the brain.

Ohio State University researchers have created a system in which two types of cells interact in a dish as they do in nature: neurons from the hippocampus and other brain cells, called oligodendrocytes, whose role is to wrap myelin around the axons.

Now that the researchers can study how myelination is switched on and off for hippocampal neurons, they also can see how myelin does more than provide insulation – it also has a role in controlling nerve impulses traveling between distant parts of the nervous system. Identifying this mechanism when myelin is present will help improve understanding of what happens when axons in this critical area of the brain lose myelin as a result of MS, researchers say.

So far, the scientists have used the system to show that myelin regulates the placement and activity of a key protein, called a Kv1.2 voltage-gated potassium channel, that is needed to maintain ideal conditions for the effective transmission of electrical signals along these hippocampal axons.

“This channel is important because it is what leads to electrical activity and how neurons communicate with each other downstream,” said Chen Gu, assistant professor of neuroscience at Ohio State and lead author of the study. “If that process is disrupted by demyelination, disease symptoms may occur.”

The study appears in the current (July 22, 2011) issue of the Journal of Biological Chemistry.

To create the cell culture system, the researchers began with hippocampus neurons from a rodent brain – a cell type that Gu has worked with for years. In culture, these cells can grow and develop dendrites – other branch-like projections off of neurons – and axons as well as generate electrical activity and synaptic connections, the same events that occur in the brain.

The researchers then added oligodendrocytes, along with some of their precursor cells, to the same dish as the neurons. And eventually, after maturing, these oligodendrocytes began to wrap myelin around the axons of the hippocampal neurons.

This system takes about five weeks to create, but the trickiest part, Gu said, was developing the proper solution for this culture so that both kinds of cells would behave as nature intended.

“In the end, the composition of the culture medium is basically half from a solution that supports the neurons and half from a medium in which the oligodendrocytes function well. We know that all the cells were happy because we got myelin,” said Gu, also an investigator in Ohio State’s Center for Molecular Neurobiology.

With the system established, they then turned to experimentation to test the effects of the myelin’s presence on these specific brain cells.

Nerve cells send their signals encoded in electrical impulses over long distances. Concerted actions of various ion channels are required for properly generating these nerve impulses. Potassium channels are involved at the late phase in an impulse, and its role is to return a nerve cell to a resting state after the impulse has passed through it and gear up for the next one. The Kv1.2 ion channel helps ensure that this process works smoothly.

By experimentally manipulating signal conditions with the new co-culture system, Gu and his colleague were able to establish part of the sequence of events required for myelinated hippocampal neurons to effectively get their signals to their targets. Starting with a protein known to be produced by myelin and axons, called TAG-1, a cell adhesion molecule, they traced a series of chemical reactions indicating that myelin on the hippocampal axons was controlling the placement and activity of the Kv1.2 ion channel.

“The analysis allowed us to see the signaling pathways involving myelin’s regulation of the Kv1.2 channel’s placement along the axon as well as fine-tuning of the channel’s activity,” Gu said.

When MS demyelinates these axons, the affected nerve cells don’t get the message to rest, and subsequently can’t prepare adequately to receive and transmit the next signal that comes along.

“This means a nerve impulse will have a hard time traveling through the demyelinated region,” Gu said. “This shows that the ion channel is probably involved in the downstream disease progression of MS.”

Gu envisions many additional uses for the new co-culture system, including additional studies of how myelin affects the behavior of other channels, proteins and molecules that function within axons, as well as to screen the effects of experimental drugs on these myelinated cells.

This work was supported by a Career Transition Fellowship Award from the National Multiple Sclerosis Society and a grant from the National Institute for Neurological Disorders and Stroke.

Source: PhysOrg.com © PhysOrg.com™ 2003-2011 (22/07/11)

Join our new social network www.shineonms.com

Enhanced by Zemanta

New Australian research has found a link between glandular fever and multiple sclerosis (MS).

MS affects 20,000 people in Australia and is a condition where the immune system attacks the brain and spinal cord.

Many of those diagnosed are young, healthy women.

Now a new study from the Australian National University (ANU) has found those who have glandular fever antibodies have a much greater risk of developing multiple sclerosis.

The research, published in the journal Neurology, could lead to new treatments for the condition.

ANU Associate Professor Robyn Lucas studied 300 patients with MS and 500 healthy participants.

She also found a strong relationship between those who had MS and genetic changes relating to the immune system.

Professor Lucas says the findings are consistent with other studies showing an association between markers of past episodes of glandular fever and MS risk.

“We have shown further interaction with other immune system genes in the HLA class 1 region and CLTA-4,” she said.

Professor Lucas says the Australian work is promising.

“It starts to bring together the different risk factors that we know are involved in MS. It points us in the right direction for further research to prevent and cure MS,”she said.

The research was part of the Ausimmune study, a major study looking at the possible environmental triggers for multiple sclerosis.

Source: ABC News © 2011 ABC (22/07/11)

Join our new social network www.shineonms.com

Enhanced by Zemanta

MS campaigner and health activist Ryan McLaughlin from Glasgow, founder of the Shine on Scotland campaign to prevent MS has launched his very own social network dedicated to fighting for better rights for those with MS and beating multiple sclerosis –  shineoms.com.

Shine on MS is free to join to anyone effected or touched by MS including charities and MS organisations alike. The new platform will act as central campaigns hub to allowing us to launch and support MS campaigns anywhere in the world and to easily manage the logistics via a single platform – it-s fantastic.

The new website forming a key part of the campaign’s vision to help in the fight to ’beat MS’ .

The shineonms.com social network will not only offer many of the applications and tools available on Facebook but it also offers apps usually only available to users on premium paid for websites such as Hoot suite.

The website also offers members the ability to customise their own profile pages similar to that offered by social sites like MySpace and Bebo

We have worked hard on easy integration between both Facebook and twitter a key goal, both these platforms have been key to our success so far but the ability to have one website that can provide a platform to bring everyone in the world with MS onto one website who share one goal ending MS – I believe to be key to beating this disease.

Advice & Support

The teenager has vowed to support other children or groups wishing to help improve the lives of those with MS by taking direct action and looking for help to get started .

For the last month it has been undergoing trials by friends and fans of the campaign and while is site still being developed it’s now live and open to everyone effected by MS is invited to join and share your thoughts.

“I want to let members shape the network and get  involved in helping develop not only the website but shaping a new campaign for ‘Global Political Action on MS ‘ We have built this website for the MS community now we need everyone in the MS community to join us and have a say to make it succeed”

Have your say and get involved at http://www.shineonms.com

Teenage dream: Katy Perry shows some love for gigantic Justin Bieber Four weeks after she partied with 14-year-old Rebecca Black in her “Last Friday Night (T.G.I.F.)” video, Katy Perry is living the teenage dream all over again — only this time, it's with Canadian mini-heartthrob Justin Bieber. Or at least with a giant painting of him. Perry tweeted a photo of herself Saturday posing next to what looks to be a 10-foot … Read More

via PopWatch

 

Pills, IUDs and patches without the co-pay? A new report says free and accessible birth control is an essential part of a full range of preventive health services that should be offered to all American women as part of the Patient Protection and Affordable Care Act (ACA) of 2010. With the ACA came a new emphasis on preventive care as a cost-saving and effective way to pre-empt illnesses and cut medical costs. As Kate Pickert reported over on TIME … Read More

via TIME Healthland

 

The biotechnological companies Advancell and Neurotec Pharma, both based in Barcelona Science Park (PCB), Spain, have announced the initiation of a clinical Phase IIa study with NT-KO-003, an innovative oral therapy for multiple sclerosis (MS). NT-KO-003 was codeveloped by both companies and its mechanism of action is completely different from the drugs currently used to treat this disease.

The clinical trial, called NeuroAdvan, will be conducted in 105 patients from 11 hospitals in Spain (4 of them in Catalonia) and 3 in Germany, and will be led by Dr Pablo Villoslada, director of Neuroimmunology at IDIBAPS, Hospital Clínic de Barcelona, Spain. The project is being conducted in collaboration with the MRI Analysis and Research Center in Neuroimaging and Multiple Sclerosis (CARM) at the Hospital Vall d’Hebron, Barcelona, led by Dr. Alex Rovira, and also with advice from Dr. Rafael Arroyo at the San Carlos Cinical Hospital, Madrid, Spainm and Dr. Xavier Montalban from Hospital Vall d’Hebron, Spain. Results from the study are expected in late 2012.

MS affects about 30,000 people in Spain according to the Spanish Association of Multiple Sclerosis, and about 2.5 million worldwide, according to World Health Organization (WHO). MS mainly affects young adults (mostly women), aged between 20 and 50. The drugs currently used to treat MS are immunomodulators with significant side effects, limited effectiveness and require parenteral administration (intravenous or subcutaneous), thus making adherence to the therapies difficult.

In animal models during the preclinical phase, NT-KO-003 has demonstrated an anti-inflammatory and neuroprotective effect, rather than an immunosuppressive effect. Consequently, NT-KO-003 can be combined with other drugs when necessary without increasing toxicity and can be administered to nearly all patients affected by the disease. It is also one of the first oral treatments that can potentially slow the progression of MS and reduce the neurological damage caused by the disease.

Because of its neuroprotective mechanism of action, Advancell and Neurotec are exploring the possibility of using NT-KO-003 in the treatment of other neuromuscular diseases, such as amyotrophic lateral sclerosis, which mainly affects men aged between 40 and 70 and causes the death of 50% of patients it in the first three years after the onset of symptoms.

According to the project managers at Advancell, Mercè de Frias, and Neurotec Pharma, Javier Bustos, “the promising results of NT-KO-003 in animals convinced us to start clinical trials in MS patients. We managed to involve doctors and patients’ associations in the design of the trial protocol and we believe the study meets the current needs of MS patients”

“At present, the main concern of MS patients is to maintain a good quality of life. They need to stop the progression of the disease, or at least to slow down, and if possible to recover from the serious side-effects. Since MS is a chronic disease that affects young people who are working and have families, new treatments should be easy to manage and should have no side effects, so as not to interfere with patients lives. NT-KO-003 holds great great promise because of its safety and ease-of-use, which are very good, and unlike current drugs it does not alter patients’ quality of life, and also because it’s mechanism of actionis new and complementary to existing treatments”, says Dr. Villoslada. “Furthrmore, all the neurologists participating in this study are really motivated because this treatment has arisen from basic research done by colleagues from our country and may be beneficial to our patients. This is an example of real innovation”.

An investment of EUR 2.2 million will be made in this clinical trial, and Advancell and Neurotec Pharma will receive funding support from the Catalan Local Government, through the Nuclis of Technological Innovation Program of ACC1Ó, and from the Ministry of Science and Innovation, through the subprogram INNPACTO, which is part of the National Plan for Scientific Research, Technological Development and Innovation 2008-2011 (IPT-010000-2010-035). Both programs are financed by the European Regional Development Fund (FEDER). The total cost of NT-KO-003 development is about EUR 4 million, with an estimated potential market of around EUR 5.3 billion.

This project will lead to clinical proof of concept of the first molecule arising from Neurotec’s research and Advancell reaffirms its business model of developing new drugs to Phase II,. Once the trial has been successfully completed, both companies plan to license the drug to a pharmaceutical company, which will continue its development and bring it to market.

According to the director of the Advancell’s Therapeutics Unit, Clara Campàs and Advancell´s CEO, Kenneth Weissmahr, “with this project, Advancell demonstrates its know-how in drug development and shows its commitment to develop projects with significant social and economic return in addition to responding to a difficult disease with significant therapeutic needs “

According to the CEO of Neurotec Pharma, Marco Pugliese, “this clinical trial is the proof that projects born in the universitary environment can be successfully translated to the business world and quickly arrive to the patients thanks to a reprofiling strategy, which is increasingly used to develop new therapies”.

Source: Advancell (19/07/11)

Enhanced by Zemanta